

COVID-19 VACCINE SUPPLY CHAIN: HOW WE WILL VACCINATE THE GLOBE

The COVID-19 pandemic has challenged the global vaccine supply chain in an unprecedented way. As billions of people need vaccines around the world, the demand for raw materials, manufacturing capabilities, and distribution capacity has skyrocketed. To ensure people get safe and effective vaccines as quickly as possible, biotechnology companies have leveraged global partnerships and innovative collaborations to reach patients all around the world. It is critically important to support the ability of innovators to scale up manufacturing. Vaccine makers are set to produce nearly 11 billion doses — that's enough supply to vaccinate all high-risk patients across the globe. And there's even more to come as additional new vaccines are expected to be approved for use.

Manufacturing Partnerships and Doses Committed

Across six of the leading COVID-19 vaccine makers, nearly 300 total partnerships have boosted manufacturing of vaccines as of June 2021. These innovative collaborations will drive the production of billions of vaccine doses in many countries around the world.

Vaccine Maker	Partnerships	Estimated Doses 2021-2022	Geographic Partnerships/ Manufacturing Sites
AstraZeneca	6+	3 billion	۹ ۲ ۲
	10+	300 million	€●00≎≎
Johnson-Johnson	10+	1.5 billion	≝●३००≽
moderna	10+	4 billion	
NOVAVAX	20+	1.1 billion	
Pfizer BIONTECH	5+	7 billion	≜●()\$@ () (
Source: Press Release Data, June 2021			

Vaccine Production Across the Globe


Many countries around the world are helping produce COVID-19 vaccines. As of June 2021, every country highlighted is involved in some part of the manufacturing process.





Billions of Vaccine Doses Expected

According to June 2021 forecasts, vaccine production could generate nearly 11 billion doses if the ability to scale up manufacturing is not jeopardized. That is enough supply to vaccinate all high-risk patients across the globe.



Doses Committed to COVAX and Other Regional Organizations (as of June 2021)

Many vaccine makers have also committed hundreds of millions of vaccines in 2021-2022 to COVAX, a global program focused on delivering COVID treatments to patients in poor and under-developed countries. As of June 2021, COVAX has shipped over 80 million doses to 129 participating countries. In addition to bilateral deals, vaccine manufacturers have committed doses to low- and middle-income countries through regional deals.

